Can we consider procalcitonin as a consolidated biomarker in sepsis management?
A. Garcia-de-Lorenzo, S.M. Sanchez
Citation Information :
Garcia-de-Lorenzo A, Sanchez S. Can we consider procalcitonin as a consolidated biomarker in sepsis management?. Indian J Crit Care Med 2015; 19 (3):136-137.
Choudhary R, Maisel AS. Procalcitonin use to identify the infected heart failure patient. In: Vincent JL, editor. Annual Update in Intensive Care and Emergency Medicine. Berlin-Heidelberg: Springer-Verlag, Berlin Heidelberg; 2013. p. 77-83.
Jain S, Sinha S, Sharma SK, Samantaray JC, Aggrawal P, Vikram NK, et al. Procalcitonin as a prognostic marker for sepsis: A prospective observational study. BMC Res Notes 2014;7:458.
De Azevedo JR, Torres OJ, Malafaia O. Procalcitonin as a prognostic biomarker of severe sepsis and septic shock. Crit Care 2013;17:21.
Sudhir U, Venkatachalaiah RK, Kumar TA, Rao MY, Kempegowda P. Significance of serum procalcitonin in sepsis. Indian J Crit Care Med 2011;15:1-5. [Last accessed on 2015 Feb 15].
Poddar B, Gurjar M, Singh S, Aggarwal A, Singh A, Azim A, Baronia A. Procalcitonin kinetics as a prognostic marker in severe sepsis/septic shock. Ind J Crit Care Med 2015;19:140-146.
Available from: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm.
Maseda E, Suarez-de-la-Rica A, Anillo V, Tamayo E, García-Bernedo CA, Ramasco F, et al. Procalcitonin-guided therapy may reduce length of antibiotic treatment in intensive care unit patients with secondary peritonitis: A multicenter retrospective study. J Crit Care 2014. [Epub ahead print].
Soni NJ, Samson DJ, Galaydick JL, Vats V, Pitrak DL, Aronson N. Procalcitonine-Guided Antibiotic Therapy. Comparative Effectiveness. Reviews, No. 78. Agency for Healthcare and Quality (US). Report No.: 12 (13)-EHC124-EF; Oct, 2012.
